All AbMole products are for research use only, cannot be used for human consumption.
X-376 is a potent and highly specific ALK small molecule tyrosine kinase inhibitors (TKIs) with IC50 of 0.61 nM. In Ambit kinome screens, cell growth inhibition studies, and surrogate kinase assays, X-376 was more potent inhibitors of ALK but less potent inhibitors of MET compared to PF-02341066. X-376 displayed potent antitumor activity in vivo with favorable pharmacokinetic and toxicity profiles.
Science. 2017 Dec 1;358(6367).
The target landscape of clinical kinase drugs
X-376 purchased from AbMole
 |
Source | Munich Industrial University (2018). Figure 36. X-376 (AbMole BioScience) |
| Method | Kinase binding of small molecule inhibitors | |
| Cell Lines | BT-474 cells, Caki-1 cells, KM-12 and HEK-293 cells | |
| Concentrations | 1 μM | |
| Incubation Time | 24 h | |
| Results | Notably, the photosensitizing effect of small molecule inhibitors can also be used for photodynamic therapy of cancer. |
 |
Source | Science (2017). Figure 4. X-376 (Abmole Bioscience) |
| Method | Cell viability and proliferation assays | |
| Cell Lines | A-431 and ACHN cells | |
| Concentrations | 50 nM | |
| Incubation Time | 72 h | |
| Results | Regardless of whether or not EGFR carried an activating mutation, the combination was always more effective in inhibiting cell viability and proliferation than any one drug alone. |
| Molecular Weight | 547.41 |
| Formula | C25H25Cl2FN6O3 |
| CAS Number | 1365267-27-1 |
| Solubility (25°C) | DMSO 90 mg/mL |
| Storage |
Powder -20°C 3 years ; 4°C 2 years In solvent -80°C 6 months ; -20°C 1 month |
| Related ALK Products |
|---|
| TL13-22
TL13-22 is a negative control for TL13-12 and a potent ALK inhibitor with an IC50 of 0.54 nM. |
| TL13-110
TL13-110 is a negative control for TL13-112 and a potent ALK inhibitor with an IC50 of 0.34 nM. |
| ALK inhibitor 2
ALK inhibitor 2 is a potent pyrimidin ALK inhibitor. |
| NVL-655 TFA
NVL-655 (ALK-IN-27) TFA is a novel, brain-permeable, selective ALK inhibitor with antitumor activity. For Ba/F3 CLIP1-LTK cells, NVL-655 (ALK-IN-27) TFA has an IC50 of 2.7 nM. It can be used in studies related to ALK-positive non-small cell lung cancer (NSCLC). |
| Neladalkib
Neladalkib (NVL-655, ALK-IN-27) is a novel, brain-permeable, selective ALK inhibitor with antitumor activity. For Ba/F3 CLIP1-LTK cells, NVL-655 has an IC50 of 2.7 nM. Neladalkib (NVL-655, ALK-IN-27) can be used in studies related to ALK-positive non-small cell lung cancer (NSCLC). |
All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
